Effects of Guizhi decoction for diabetic cardiac autonomic neuropathy

Abstract

Background: Diabetic cardiac autonomic neuropathy (DCAN) is one of the serious complications of diabetes. The pathogenesis of DCAN has not been fully elucidated. There is currently no effective treatment for such chronic disease. Traditional Chinese medicine has a long clinical history for the prevention and treatment of diabetes and chronic complications, and it also shows certain advantages in the treatment of DCAN. Many clinical studies have confirmed that Chinese medicine Guizhi decoction can reduce the clinical symptoms and improve neuronal function of patients with DCAN. So we intend to conduct a systematic review further clarified the effectiveness and safety of Guizhi decoction for DCAN. Methods: We will search each database from the built-in until July 2020. The English literature mainly searches Cochrane Library, PubMed, EMBASE, and Web of Science, while the Chinese literature comes from CNKI, CBM, VIP, and Wangfang database. Simultaneously we will retrieval clinical registration tests and grey literatures. In this study, only the clinical randomized controlled trials (RCTs) were selected to evaluate the efficacy and safety of Guizhi decoction in the treatment of DCAN. The 2 researchers independently conducted literature selection, data extraction, and quality assessment. Statistical heterogeneity among studies will be evaluated using the Cochran Q test (x 2 ) and the I 2 statistical value. We will utilize the Review Manage software V5.3.0 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) to statistically analyze all data. Ethics and dissemination: This study is a protocol for a systematic review of Guizhi decoction as a treatment of DCAN patients. Results: This study will provide high-quality synthesis of effectiveness and safety of Guizhi decoction for DCAN. Conclusion: This systematic review aims to provide new options for Guizhi decoction treatment of DCAN in terms of its efficacy and safety. Registration number: INPLASY202080018.

Potential mechanisms of Guizhi decoction against hypertension based on network pharmacology and Dahl salt-sensitive rat model

“…GZD is wildly used to treat many internal diseases, including allergic or respiratory diseases, endocrine system disease, nervous system disease, and cardiac autonomic neuropathy [ 25 ]. Additionally, GZD has accumulated plentiful experiences in the treatment of cardiovascular diseases, such as hypertension [ 11 , 12 , 26 ]. However, its material basis and potential mechanisms have not been fully elucidated.…”

“…Additionally, we found that GZD significantly improved heart rate variability and vagus nerve activity, which are associated with the progression of hypertension [ 10 ]. A meta-analysis confirmed the beneficial effect and safety of GZD in the treatment of diabetic cardiac autonomic neuropathy [ 12 ]. Zheng et al reported that GZD associated formulas exerted significant effects on the attenuation of moderate-severe painful diabetic peripheral neuropathy [ 13 ].…”

Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus

“…Диабетическая кардиомиопатиявыраженное осложнение сахарного диабета. СД приводит к функциональным и структурным изме нениям сердца независимо от гипертонии, атеро склероза коронарных артерий или любого другого сердечного заболевания, и это подтверждает диа бетическую кардиомиопатию [7]. Одна из основ ных теорий причинности диабетической кардио миопатии -диабетическая нейропатия, которая приводит к симпатической денервации, изменя ющей кровоток миокарда, что влияет на его пер фузию и приводит к отсутствию загрудинной боли [8].…”